for people ages 18-75 (full criteria)
at UC Davis UC Irvine UCLA UCSD
study started
completion around
Principal Investigator
by Gary Schiller (ucla)



This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

Official Title

A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia


Acute Myeloid Leukemia, AML, Relapsed AML, Refractory AML, Leukemia, Myeloid Leukemia, Leukemia, Myeloid, Acute, Uproleselan, Uproleselan (GMI-1271)


You can join if…

Open to people ages 18-75

  • ≥18 years and ≤75 years in age
  • Patients with relapsed or refractory AML
  • No more than one prior stem cell transplant
  • Has not received the chemotherapy regimen to be used for induction on this trial
  • Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial

You CAN'T join if...

  • Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML.
  • Active signs or symptoms of CNS involvement by malignancy.
  • Stem cell transplantation ≤4 months prior to dosing.
  • Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing.
  • Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing.
  • Inadequate organ function.
  • Abnormal liver function.
  • Known active infection with hepatitis A, B, or C, or human immunodeficiency virus.
  • Moderate kidney dysfunction (glomerular filtration rate <45 mL/min).
  • Uncontrolled acute life-threatening bacterial, viral, or fungal infection.
  • Clinically significant cardiovascular disease.
  • Major surgery within 4 weeks of dosing.


  • UC San Diego Moore Cancer Center
    La Jolla California 92093 United States
  • University of California, Los Angeles - UCLA
    Los Angeles California 90095 United States
  • University of California Irvine
    Orange California 92868 United States
  • UC Davis Comprehensive Cancer Center
    Sacramento California 95817 United States
  • Stanford Cancer Institute
    Palo Alto California 94304 United States

Lead Scientist at University of California Health

  • Gary Schiller (ucla)
    Professor-in-Residence, Medicine. Authored (or co-authored) 155 research publications


in progress, not accepting new patients
Start Date
Completion Date
GlycoMimetics Incorporated
Phase 3 research study
Study Type
About 388 people participating
Last Updated